Important:
Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.
UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.
Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.
This is the complete archive for the UpToDate Clinical Talk Podcasts.
Duration of Zika virus detection in body fluids; Underdosing of direct oral anticoagulants
Date Released: Apr 19 2017
This podcast features Dr. Martin Hirsch, discussing persistence of Zika virus in body fluids; and Dr. Mark Crowther, discussing underdosing of direct oral anticoagulants (DOACs). Dr. Jennifer Tirnauer hosts. Standard dosing of direct oral anticoagulants table in UpToDate (referenced in the segment on underdosing of DOACs) Listen to the full podcast by pressing the Play Button below, or jump to the segment on duration of Zika virus in body fluids, or the segment on underdosing of DOACs.
Dr. Martin Hirsch is Professor of Medicine at the Harvard Medical School, Professor of Infectious Diseases and Immunology at the Harvard School of Public Health, and Senior Physician in Infectious Diseases at Massachusetts General Hospital in Boston.
Dr. Mark Crowther is Professor and Chair of the Department of Pathology at McMaster University in Ontario.Segment on duration of Zika virus in body fluids (Dr. Hirsch):
- Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika Virus in Body Fluids - Preliminary Report. N Engl J Med 2017.
Segment on underdosing of DOACs (Dr. Mark Crowther):
- Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017; 117:382.
Martin S Hirsch, MD Nothing to disclose.
Mark Crowther, MD, MSc Consultant/Advisory Boards: Portola, Boehringer-Ingelheim [anticoagulation reversal (andexanet, idarucizumab]).
Treatment for acute otitis media in young children; Tenofovir alafenamide for chronic hepatitis B
Date Released: Apr 5 2017
This podcast features Dr. Sheldon Kaplan, discussing the duration of antibiotic treatment in young children with acute otitis media; and Dr. Anna Lok, discussing the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Dr. Jennifer Mitty hosts. Listen to the full podcast by pressing the Play Button below, or jump to the segment on acute otitis media, or the segment on tenofovir alafenamide.
Dr. Sheldon Kaplan is Professor of Pediatrics and head of the Pediatric Infectious Disease section at Baylor College of Medicine, as well as Chief of the Infectious Disease service and head of the Department of Pediatric Medicine at Texas Children's Hospital.
Dr. Anna Lok is the Alice Lohrman Andrews Research Professor in Hepatology in the Department of Internal Medicine at the University of Michigan in Ann Arbor and the Director of Clinical Hepatology and Assistant Dean for Clinical Research.Segment on otitis media (Dr. Kaplan):
- Hoberman A, Paradise JL, Rockette HE, et al. Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children. N Engl J Med 2016; 375:2446.
Segment on tenofovir alafenamide (Dr. Lok):
- Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:185.
- Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1:196.
Sheldon L Kaplan, MD Grant/Research/Clinical Trial Support: Pfizer [S. pneumoniae (PCV13, Linezolid)]; Cubist [S. aureus (Tedizolid)]; Forest Lab [Osteomyelitis (Ceftaroline)]. Consultant/Advisory Boards: Pfizer [S. pneumoniae (PCV13, Linezolid); S. aureus (vaccine development)]; Theravance [S. aureus (Telavancin)].
Anna SF Lok, MD Grant/Research/Clinical Trial Support: Gilead [HBV/HCV]; Bristol-Myers Squibb [HCV]; Merck [HCV]. Consultant/Advisory Boards: Gilead (declined honorarium) [HBV/HCV]; Tekmira [HBV (Preclinical studies)].
Metformin use in diabetes; Flexible sigmoidoscopy and colorectal cancer screening in older women
Date Released: Mar 22 2017
This episode features Dr. David Nathan, discussing clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease; and Dr. Chyke Doubeni, discussing the effectiveness of screening for colorectal cancer using flexible sigmoidoscopy in men and women at different age groups. Dr. Nancy Sokol hosts.
Dr. David Nathan is a Professor of Medicine at Harvard Medical School and Director of the Clinical Research Center and Diabetes Center at Massachusetts General Hospital in Boston.
Dr. Chyke Doubeni is Chair and Presidential Associate Professor in the Department of Family Medicine and Community Health at the Perelman School of Medicine, University of Pennsylvania.Segment on metformin use (Dr. Nathan):
- Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med 2017; 166:191.
Segment on screening for colorectal cancer using flexible sigmoidoscopy (Dr. Doubeni):
- Holme Ø, Schoen RE, Senore C, et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ 2017; 356:i6673.
David M Nathan, MD Nothing to disclose
Chyke Doubeni, MD, FRCS, MPH Nothing to disclose
Determining CPR futility for out-of-hosp cardiac arrest; Hep C management in liver transplantation
Date Released: Mar 8 2017
In this episode, Dr. Charles Pozner discusses criteria for determining futility for resuscitation for out-of-hospital cardiac arrest and potential implications for organ donation; and Dr. Robert Brown discusses management of hepatitis C infection in patients undergoing liver transplantation. Listen to the full podcast by pressing the Play Button below, or jump to the segment on determining CPR futility for out-of-hospital cardiac arrest, or the segment on hepatitis C management in liver transplantation. .
Dr. Charles Pozner is an Associate Professor at Harvard Medical School, Medical Director of the STRATUS Center for Medical Simulation, and an emergency medicine physician at Brigham and Women’s Hospital in Boston.
Dr. Robert Brown is a Professor of Medicine and Clinical Chief of the Division of Gastroenterology and Hepatology at the Weill Cornell Medical Center in NYC.Segment on futility of resuscitation following cardiac arrest (Dr. Pozner):
- Jabre P, Bougouin W, Dumas F, et al. Early Identification of Patients With Out-of-Hospital Cardiac Arrest With No Chance of Survival and Consideration for Organ Donation. Ann Intern Med 2016; 165:770.
Segment on management of Hepatitis C in patients undergoing liver transplantation (Dr. Brown):
- Levitsky J, Verna EC, O'Leary JG, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. N Engl J Med 2016; 375:2106.
Charles N Pozner, MD Nothing to disclose
Robert S Brown, Jr, MD, MPH Grant/Research/Clinical Trial Support: Gilead; Bristol-Myers Squibb; Janssen; AbbVie; Merck; [Hepatitis C, ALF (various direct-acting agents for HCV, bioartificial liver devices)]. Consultant/Advisory Boards: Gilead; Bristol-Myers Squibb; Janssen; AbbVie; Merck; Vital Therapies [Hepatitis B and C, ALF (various direct-acting agents for HCV, bioartificial liver devices)].